JP2023100679A5 - - Google Patents

Download PDF

Info

Publication number
JP2023100679A5
JP2023100679A5 JP2023066568A JP2023066568A JP2023100679A5 JP 2023100679 A5 JP2023100679 A5 JP 2023100679A5 JP 2023066568 A JP2023066568 A JP 2023066568A JP 2023066568 A JP2023066568 A JP 2023066568A JP 2023100679 A5 JP2023100679 A5 JP 2023100679A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023066568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023100679A (ja
Filing date
Publication date
Priority claimed from GBGB1705686.2A external-priority patent/GB201705686D0/en
Application filed filed Critical
Publication of JP2023100679A publication Critical patent/JP2023100679A/ja
Publication of JP2023100679A5 publication Critical patent/JP2023100679A5/ja
Pending legal-status Critical Current

Links

JP2023066568A 2017-04-07 2023-04-14 新規化合物及びそれらの治療上の使用 Pending JP2023100679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1705686.2A GB201705686D0 (en) 2017-04-07 2017-04-07 Novel compounds and therapeutic uses thereof
GB1705686.2 2017-04-07
JP2019554924A JP7695773B2 (ja) 2017-04-07 2018-04-06 新規化合物及びそれらの治療上の使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019554924A Division JP7695773B2 (ja) 2017-04-07 2018-04-06 新規化合物及びそれらの治療上の使用

Publications (2)

Publication Number Publication Date
JP2023100679A JP2023100679A (ja) 2023-07-19
JP2023100679A5 true JP2023100679A5 (enExample) 2025-06-17

Family

ID=58744828

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554924A Active JP7695773B2 (ja) 2017-04-07 2018-04-06 新規化合物及びそれらの治療上の使用
JP2023066568A Pending JP2023100679A (ja) 2017-04-07 2023-04-14 新規化合物及びそれらの治療上の使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019554924A Active JP7695773B2 (ja) 2017-04-07 2018-04-06 新規化合物及びそれらの治療上の使用

Country Status (12)

Country Link
US (1) US11766483B2 (enExample)
EP (1) EP3606561B1 (enExample)
JP (2) JP7695773B2 (enExample)
KR (1) KR102646581B1 (enExample)
CN (1) CN110753558B (enExample)
AU (1) AU2018248706B2 (enExample)
CA (1) CA3059018A1 (enExample)
ES (1) ES2954294T3 (enExample)
GB (1) GB201705686D0 (enExample)
IL (1) IL270460B2 (enExample)
WO (1) WO2018185495A1 (enExample)
ZA (1) ZA201906580B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
FR2801305B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
FI20011664L (fi) 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
JP2005535723A (ja) 2002-08-20 2005-11-24 バイオティ セラピィーズ コープ 腫瘍特異的オリゴ糖エピトープおよびその用途
US7585886B2 (en) * 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
WO2009134891A2 (en) * 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
CA2716622A1 (en) 2008-02-26 2009-09-03 The Regents Of The University Of California Glycopeptides and methods of making and using them
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP6111276B2 (ja) * 2012-03-17 2017-04-05 ポリフォー・アクチェンゲゼルシャフトPolyphor Ag コンホメーション制約された全合成されたマクロ環化合物
US9556167B2 (en) * 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
AU2015282627B2 (en) * 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof
US11014966B2 (en) * 2016-09-13 2021-05-25 Centuari Therapeutics Limited Compounds and therapeutics uses thereof

Similar Documents

Publication Publication Date Title
JP2023113641A5 (enExample)
JP2024156852A5 (enExample)
JP2024133471A5 (enExample)
JP2024037765A5 (enExample)
JP2023164986A5 (enExample)
JP2025106258A5 (enExample)
JP2025023938A5 (enExample)
JP2024156705A5 (enExample)
JP2023134519A5 (enExample)
JP2023103231A5 (enExample)
JP2025118771A5 (enExample)
JP2025038009A5 (enExample)
JP2023139025A5 (enExample)
JP2018100276A5 (enExample)
JP2025165966A5 (enExample)
JP2025124655A5 (enExample)
JP2025041678A5 (enExample)
JP2024038101A5 (enExample)
JP2024160274A5 (enExample)
JP2018012698A5 (enExample)
JP2022166039A5 (enExample)
JP2018101814A5 (enExample)
EP4003572A4 (en) TEXTURED SORBENT SHEETS, ASSEMBLIES CONTAINING THEM, AND MOLDS FOR THE MANUFACTURE THEREOF
JP2023166412A5 (enExample)
JP2012500203A5 (enExample)